TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34369227

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for insomnia (seven sessions over a maximum of 12 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for insomnia
Number of subjects: 100
Study: 34233921

Group type: EXPERIMENTAL
Intervention: belatacept/alemtuzumab
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: belatacept/rATG
Number of subjects: 316

Group type: COMPARATOR
Intervention: tacrolimus/rATG
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: belatacept
Number of subjects: 316
Study: 33681908

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (15 sessions of 90 minutes each)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 0
Study: 32842183

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment once a day for 10 consecutive days (20 treatments total)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment twice per day for a total of 10 days
Number of subjects: 107

Group type: COMPARATOR
Intervention: No hyperbaric oxygen therapy (control group)
Number of subjects: 107
Study: 33047878

Group type: EXPERIMENTAL
Intervention: WHO Grades 1 and 2 bleeds
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Hematuria
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: WHO Grades 3 and 4 bleeds
Number of subjects: 315
Study: 32391656

Group type: EXPERIMENTAL
Intervention: n-3 FA-enriched oral nutrition supplement (ONS) twice daily for 7 days before and after surgery
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: n-3 FA-enriched oral nutrition supplement (ONS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: standard ONS
Number of subjects: 148
Study: 36718715

Group type: EXPERIMENTAL
Intervention: Remote Patient Management (RPM) with HeartNetCare-HF
Number of subjects: 1022

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1022
Study: 34959797

Group type: EXPERIMENTAL
Intervention: BCAA supplementation with standard-protein diet
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard-protein diet with placebo (CT)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: High-protein diet (27%) with placebo
Number of subjects: 111
Study: 35688053

Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous flumazenil infusions (4 mg/24 h for approximately eight days)
Number of subjects: 26
Study: 32249198

Group type: EXPERIMENTAL
Intervention: Varying music (VM: instrumental music with incremental variations in tempo and octave)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Stable music (SM: instrumental music without such variations)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Silence (control intervention)
Number of subjects: 21
Study: 32343462

Group type: EXPERIMENTAL
Intervention: Inotersen for 39 cumulative months
Number of subjects: 135

Group type: COMPARATOR
Intervention: Switch from placebo to inotersen in the OLE
Number of subjects: 135
Study: 34752205

Group type: EXPERIMENTAL
Intervention: Pure physical activity
Number of subjects: 22

Group type: COMPARATOR
Intervention: Physical/attentional training
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 22
Study: 32646835

Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison between kneeling and standing positions
Number of subjects: 37
Study: 35343754

Group type: EXPERIMENTAL
Intervention: EN solution + probiotics + 90 ml of pectin
Number of subjects: 60
Study: 32270347

Group type: EXPERIMENTAL
Intervention: Bolus intermittent furosemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous infusion of furosemide
Number of subjects: 0
Study: 35970035

Group type: EXPERIMENTAL
Intervention: S-IROX (S-1, irinotecan, and oxaliplatin combination therapy)
Number of subjects: 45
Study: 33129705

Group type: EXPERIMENTAL
Intervention: Music and analgesic medication
Number of subjects: 50

Group type: COMPARATOR
Intervention: Analgesic medication only
Number of subjects: 50
Study: 32032692

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 34612190

Group type: EXPERIMENTAL
Intervention: MIND Diet Intervention
Number of subjects: 604
Study: 34960107

Group type: EXPERIMENTAL
Intervention: Documentary intervention
Number of subjects: 574
Study: 32592414

Group type: EXPERIMENTAL
Intervention: Solution‐Oriented Approach Intervention (SOAI)
Number of subjects: 0
Study: 32978020

Group type: EXPERIMENTAL
Intervention: Knee joint sounds recorded during standing up from/sitting down on a bench
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Knee joint sounds recorded during descending stairs
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Knee joint sounds recorded during passive movement, 10% and 40% loading of the individual one repetition maximum
Number of subjects: 12
Study: 35131497

Group type: EXPERIMENTAL
Intervention: Monofilament suture (polyglytone 6211 [Caprosyn])
Number of subjects: 300

Group type: COMPARATOR
Intervention: Multifilament suture (coated polyglactin 910 with Triclosan [Vicryl Plus])
Number of subjects: 300
Study: 33524368

Group type: EXPERIMENTAL
Intervention: Guselkumab (IL-23p19 blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab (IL-17A blocker)
Number of subjects: 0
Study: 32187236

Group type: EXPERIMENTAL
Intervention: Internet-based Mind/Body Program for Fertility
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 71
Study: 33325311

Group type: EXPERIMENTAL
Intervention: Family engagement in treatment
Number of subjects: 141

Group type: COMPARATOR
Intervention: Opioid Assisted Treatment (OAT)
Number of subjects: 141
Study: 34039768

Group type: EXPERIMENTAL
Intervention: Walking School Bus (WSB) program
Number of subjects: 418
Study: 34957550

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) treatment, mean modal dose 27 mg/kg/day, median treatment time 267 days (range 18-910).
Number of subjects: 201
Study: 32026713

Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misspecified information growth
Number of subjects: 0
Study: 34585216

Group type: EXPERIMENTAL
Intervention: Multidomain Intervention (MI) + Polyunsaturated Fatty Acids (PFA)
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Multidomain Intervention (MI) alone
Number of subjects: 1525

Group type: EXPERIMENTAL
Intervention: Polyunsaturated Fatty Acids (PFA) alone
Number of subjects: 1525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1525
Study: 32969693

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (PA)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sedentariness
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Light physical activity (PA)
Number of subjects: 228
Study: 36107990

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Stretching and toning (SAT)
Number of subjects: 73
Study: 33476675

Group type: EXPERIMENTAL
Intervention: Social exclusion (n = 88)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Social inclusion (n = 81)
Number of subjects: 169
Study: 616683703

Group type: EXPERIMENTAL
Intervention: 4 Pillars Practice Transformation Program
Number of subjects: 14
Study: 35785498

Group type: EXPERIMENTAL
Intervention: Licorice root extract (1,000 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32990794

Group type: EXPERIMENTAL
Intervention: Leucocyte-poor-platelet-rich plasma (PRP) injection at the end of surgery in group B.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no PRP injection).
Number of subjects: 64
Study: 35502128

Group type: EXPERIMENTAL
Intervention: Endoscopic incisional biopsy (EIB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bite-on-bite biopsy
Number of subjects: 70
Study: 33523763

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 300 mL daily for 2 weeks
Number of subjects: 24
Study: 35306156

Group type: EXPERIMENTAL
Intervention: Bd1 (0-4 buds)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Bd2 (5-9 buds)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Bd3 (≥10 buds)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Bd (1 versus 2-3)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Bd2 and Bd3
Number of subjects: 1048
Study: 32166405

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 1018
Study: 34608673

Group type: EXPERIMENTAL
Intervention: Maxillary sinus membrane elevation (MSME)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Maxillary sinus floor augmentation (MSFA)
Number of subjects: 40
Study: 33951361

Group type: COMPARATOR
Intervention: Exercise group (moderate-to-vigorous-intensity exercise program plus placebo)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Liraglutide group (liraglutide 3.0 mg per day plus usual activity)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Combination group (exercise program plus liraglutide therapy)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Liraglutide group
Number of subjects: 195
Study: 32227717

Group type: EXPERIMENTAL
Intervention: Huanshao Capsules (HSC) at a dose of 3 capsules tid for 4 weeks
Number of subjects: 248

Group type: COMPARATOR
Intervention: Wuziyanzong Pills at 6 g bid for 4 weeks
Number of subjects: 248
Study: 34986897

Group type: EXPERIMENTAL
Intervention: TAK228 plus weekly paclitaxel chemotherapy
Number of subjects: 124
Study: 32968804

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Combined (OCPs + Lifestyle)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lifestyle
Number of subjects: 94
Study: 35309523

Group type: EXPERIMENTAL
Intervention: Ballistic training programme using an arm/shoulder specific strength device (ASSSD), 2 sessions/week for 8 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ballistic training programme using an arm/shoulder specific strength device (ASSSD)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 26
Study: 34904950

Group type: EXPERIMENTAL
Intervention: Web-based low-FODMAP diet (LFD) for 4 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (VSL#3) for 4 weeks (2 × 450 billion colony-forming units per day)
Number of subjects: 34
Study: 32954753

Group type: EXPERIMENTAL
Intervention: PEEP titrated to achieve maximum dynamic compliance from 4 cmH2O (Group PDYN)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Zero PEEP (Group P0)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PEEP set to 2 cmH2O plus the pressure of lower inflection point (Group PLIP2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PEEP titrated to achieve maximum static compliance from averaged LIP pressure (Group PLIPS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Incremental PEEP values titrated to achieve maximum static compliance (Group PSTAT)
Number of subjects: 75
Study: 36045345

Group type: COMPARATOR
Intervention: CogniFit
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Thinking in Motion (TIM)
Number of subjects: 47
Study: 33241616

Group type: EXPERIMENTAL
Intervention: Tazarotene Clindamycin Cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tazarotene Cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Clindamycin Phosphate Gel
Number of subjects: 12
Study: 34654455

Group type: EXPERIMENTAL
Intervention: All three interventions (capacity building in disability-centred SRHRs information and service delivery for healthcare providers, support for WWDs to access disability-unfriendly healthcare infrastructure, one-on-one regular SRHRs education, information provision, and referral)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Two health facility-level interventions (capacity building in disability-centred SRHRs information and service delivery for healthcare providers, support for WWDs to access disability-unfriendly healthcare infrastructure)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Individual level intervention (one-on-one regular SRHRs education, information provision, and referral)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 680
Study: 34749555

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25mg, 0.05ml)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 5‐FU (0.1ml of 50mg/ml)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (normal saline injection)
Number of subjects: 51
Study: 32396668

Group type: EXPERIMENTAL
Intervention: Web-based film about oral health (8.5 minutes duration)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 129
Study: 33565217

Group type: EXPERIMENTAL
Intervention: Convolutional neural network (CNN) algorithm
Number of subjects: 26786
Study: 35652770

Group type: EXPERIMENTAL
Intervention: Touhy needle
Number of subjects: 201

Group type: COMPARATOR
Intervention: Quincke needle
Number of subjects: 201
Study: 32976576

Group type: EXPERIMENTAL
Intervention: Pomalidomide 0.5 mg per day orally
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pomalidomide 2 mg per day (starting at 0.5 mg per day increasing to 2 mg per day over 6 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pomalidomide (both doses)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pomalidomide (high-dose cohort)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pomalidomide (low-dose cohort)
Number of subjects: 34
Study: 32538880

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT) plus multidisciplinary physical therapy protocol (MIRT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham OMT plus multidisciplinary physical therapy protocol (MIRT)
Number of subjects: 24
Study: 35108451

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33050321

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Diet (APAD) education program
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study: 32739897

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35382883

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab (active control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32205070

Group type: EXPERIMENTAL
Intervention: Community pharmacy-based intervention (PAcHA program)
Number of subjects: 0
Study: 33186898

Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract 600 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract 300 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 33084477

Group type: EXPERIMENTAL
Intervention: Physical activity program for 3 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 35012380

Group type: EXPERIMENTAL
Intervention: High Sense of Embodiment (SoE) condition
Number of subjects: 77

Group type: COMPARATOR
Intervention: Low Sense of Embodiment (SoE) condition
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Thin-ideal avatars exposure
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Implicit measures
Number of subjects: 77
Study: 32910362

Group type: EXPERIMENTAL
Intervention: Infra-orbital first 3-point reduction and fixation (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Frontozygomatic first 3-point reduction and fixation (group A)
Number of subjects: 40
Study: 36229596

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: lithium
Number of subjects: 107
Study: 34400480

Group type: EXPERIMENTAL
Intervention: RocketAP (fully automated closed-loop control system)
Number of subjects: 18
Study: 32725102

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 36217496

Group type: EXPERIMENTAL
Intervention: NK105
Number of subjects: 123

Group type: COMPARATOR
Intervention: Paclitaxel (PTX)
Number of subjects: 123
Study: 34578984

Group type: COMPARATOR
Intervention: Weight loss intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined exercise and weight loss intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss of ≥10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of exercise and weight loss
Number of subjects: 0
Study: 33382224

Group type: EXPERIMENTAL
Intervention: PC+ERAS
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 300
Study: 34990281

Group type: EXPERIMENTAL
Intervention: PET-driven arm after 2 × BEACOPP delivering 4 × ABVD in PET2- and 4 × BEACOPP in PET2+ patients.
Number of subjects: 823

Group type: COMPARATOR
Intervention: Standard arm (6 × BEACOPP).
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Full interim PET assessment.
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Interim PET results.
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Second primary malignancy incidence.
Number of subjects: 823
Study: 33771940

Group type: EXPERIMENTAL
Intervention: Additional clothing (standardized training ensemble plus compression garments and full tracksuit)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (synthetic rugby shorts and training tee)
Number of subjects: 14
Study: 32495631

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukopenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphopenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancytopenia
Number of subjects: 0
Study: 35238296

Group type: EXPERIMENTAL
Intervention: Mesh plate (Super Fixorb MX40®; Takiron Co. Ltd., Osaka, Japan)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wire cerclage
Number of subjects: 70
Study: 32892605

Group type: EXPERIMENTAL
Intervention: Thoracoscopy-guided thoracic paravertebral block with 0.375% ropivacaine (20 ml) at thoracic 4-5 intercostal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient controlled intravenous analgesia (PCIA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thoracoscopy-guided thoracic paravertebral block
Number of subjects: 60
Study: 35961761

Group type: EXPERIMENTAL
Intervention: Secukinumab (75/150 mg based on weight)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 34391310

Group type: EXPERIMENTAL
Intervention: Drug therapy alone (Group 1)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Laser therapy (3 J/cm²) plus drug therapy (Group 2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Laser therapy (6 J/cm²) plus drug therapy (Group 3)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Drug therapy plus placebo laser therapy (Group 4)
Number of subjects: 65
Study: 32436683

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Comparison of FF/UMEC/VI with FF/VI
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Comparison of FF/UMEC/VI with UMEC/VI
Number of subjects: 10355
Study: 36229116

Group type: EXPERIMENTAL
Intervention: Behavioral rehearsal (simulated role-plays; n = 43)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Self-report (n = 41)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Chart-stimulated recall (semistructured interviews with the chart available; n = 42)
Number of subjects: 126
Study: 34616111

Group type: EXPERIMENTAL
Intervention: Quercetin-rich onion (daily quercetin intake, 50 mg as aglycone equivalent)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Quercetin-rich onion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Quercetin-free onion (placebo)
Number of subjects: 70
Study: 35124347

Group type: EXPERIMENTAL
Intervention: Acoustic lens
Number of subjects: 67

Group type: COMPARATOR
Intervention: No acoustic lens (control)
Number of subjects: 67
Study: 34621937

Group type: EXPERIMENTAL
Intervention: High frequency (HF) surveillance regimen: cystoscopy every 3 months for 2 years, then every 6 months for 2 years, then annually.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low frequency (LF) surveillance regimen: cystoscopy at 9 months following the 3-month cystoscopy, then annually.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High frequency (HF) surveillance regimen
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low frequency (LF) surveillance regimen
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 34252301

Group type: COMPARATOR
Intervention: Ravidasvir (RDV) 200 mg alone on day 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) 200 mg plus Danoprevir/Ritonavir (DNVr) 100 mg/100 mg twice daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Danoprevir/Ritonavir (DNVr) 100 mg/100 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ravidasvir (RDV) single doses of 100, 200, and 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ravidasvir (RDV) with or without DNVr
Number of subjects: 0
Study: 35532326

Group type: EXPERIMENTAL
Intervention: Remotely-delivered cancer-specific exercise education video
Number of subjects: 364

Group type: COMPARATOR
Intervention: Control group (no education video)
Number of subjects: 364
Study: 33296898

Group type: EXPERIMENTAL
Intervention: Training group (IUSim™ simulator)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6